Portola Pharmaceuticals has announced that its first Phase III study of andexanet alfa, a potential universal Factor Xa inhibitor antidote...
Portola Pharmaceuticals announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare and Janssen Pharmaceuticals, Inc....
Background: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.
Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding.
Portola Pharmaceuticals, Bristol-Myers Squibb and Pfizer Inc. announced full results from the second part of the Phase III ANNEXA-A (Andexanet...
Portola Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Direct oral anticoagulants are associated with lower rates of bleeding than vitamin K antagonists, but life-threatening bleeding still occurs. Andexanet alfa is a catalytically inactive recombinant modified human factor Xa molecule that...
Portola Pharmaceuticals announced completion of the submission of a Biologics License Application (BLA) to the FDA for its investigational agent...
One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a reversal agent. Most DOACs act by directly binding to and inhibiting the effects of factor Xa.
Portola Pharmaceuticals announced that the results of its Phase III ANNEXA study of PRT 4445 (andexanet alfa) as an antidote...